Worldwide Huntington's Disease Industry to 2029 - A Robust Product Pipeline of Disease-Modifying Treatments is Expected to Drive the Market - ResearchAndMarkets.com

2022-11-15
Business Wire
DUBLIN--(BUSINESS WIRE)--The "Huntington's Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
'Huntington\'s Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029'
The Hutington's Disease market size is estimated to be USD 475.3 million in 2021 and is expected to witness a CAGR of 21.61% during the forecast period 2022-2029.
Ingrezza's expected label expansion for treating chorea associated with Huntington's disease, the high prevalence of HD in Western countries, and a robust product pipeline of disease-modifying treatments is expected to drive the market. However, low success rate in clinical trials is expected to restrain the market growth.
Segmentation: Hutington's Disease Market Report 2021-2029
By Treatment (Revenue, USD Million)
Disease-modifying Therapies
Symptomatic Treatment
By Region (Revenue, USD Million)
North America
U.S
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of Europe
China
Japan
India
Australia
South Korea
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
GCC
Rest of MEA
Companies Mentioned
Teva (Israel)
Novartis AG (Switzerland)
GSK (UK)
AbbVie (US)
Merck (US)
Lundbeck (Denmark)
UCB (Belgium)
Acadia (US)
Sun Pharma (India)
Wockhardt (India)
Dr. Reddy's (India)
Intas (India)
US WorldMeds (US)
Zydus Cadila (India)
Cipla (India)
Strides (India)
1 A Pharma (India)
Upsher-Smith (US)
For more information about this report visit https://www.researchandmarkets.com/r/aboj38
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。